ReviewFrontiers in pharmacology2026
The efficacy of ultrasonic ablation combined with medication in the treatment of adenomyosis: a systematic review and network meta-analysis.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adenomyosis occurs when tissue from the inner lining of the endometrium grows into the muscle wall of the myometrium. Previous studies have suggested that High-Intensity Focused Ultrasound (HIFU) combined with medications may improve treatment outcomes for adenomyosis; however, the comparative efficacy of different medication combinations remains unclear. This network meta-analysis aimed to compare and rank the efficacy of various medications combined with HIFU in patients with adenomyosis. Methods: Randomized controlled trials reporting on HIFU combined with medications for adenomyosis were retrieved from 8 databases from their inception to 23 June 2025. The literature meeting the inclusion criteria was evaluated for quality and risk of bias using the Cochrane 5.1 manual and RoB2. Subsequently, a Bayesian network meta-analysis was conducted using R software. Results: A total of six interventions (HIFU + GnRH-a, HIFU + testosterone propionate, HIFU + percutaneous ethanol injection, HIFU + microbubble contrast agent, HIFU + oxytocin, and HIFU + microbubble contrast agent + oxytocin) were included to evaluate their efficacy on intraoperative indicators of adenomyosis compared with HIFU alone. A total of 8,700 records were retrieved, with 16 studies ultimately included, involving 1,685 patients with adenomyosis. Compared with HIFU alone, HIFU combined with ethanol ablation demonstrated the highest efficacy in non-perfused volume ratios (NPVR) (Mean Difference (MD) = 27, 95% Confidence Interval (CI): 2.7 to 52), sonication energy (MD = -230%, 95% CI: -290 to -180), and treatment duration (MD = -44%, 95% CI: -80 to -7.8); Additionally, HIFU combined with Gonadotropin-releasing hormone agonist (GnRH-a) showed superiority in energy efficiency factor (MD = -31%, 95% CI: -90 to -13). Conclusion: The efficacy of HIFU combined with medications in the treatment of adenomyosis is superior to that of HIFU alone. Different medications offer distinct advantages in enhancing the therapeutic effect of HIFU. Systematic Review Registration: clinicaltrials.gov, identifier CRD420251143604.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.